Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
By G. Bardy, Kerry L Lee, D. Mark, J. Poole, D. Packer, R. Boineau, M. Domanski, C. Troutman, Jill Anderson, G. Johnson and 7 more. New England Journal of Medicine, 2005
6,214 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/cf04075b17dbae3fc6bc9a3a2f9673f9fad192ea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- J. Cleland
- Gerasimos Filippatos
- Gerhard Hindricks
- M. Flemmer
- P. Marik
- J. Januzzi
- T. Horwich
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, positive): “Primary preventive ICD therapy has been shown to reduce allcause mortality in patients with reduced left ventricular ejection fraction (EF ,40%) as a result of an infarction that occurred at least 40 days earlier.(333,334) In general, ICD implantation should be deferred until at least 40 days after ”
- ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, methodology): “A few studies and one meta-analysis of several large studies have shown reduction in SCD using amiodarone for LV dysfunction due to prior MI and nonischemic dilated cardiomyopathy (DCM) (39–41), but the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) showed no survival benefit from amiodarone”
- An entirely subcutaneous implantable cardioverter-defibrillator. (2010, result): “This explains the relative younger age of these patients and the high percentage of patients with inherited diseases at baseline compared with conventional ICD populations in other studies (1,3,4).”
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, methodology): “These patients were randomized to placebo, amiodarone, or an ICD, in addition to conventional treatment including an ACE inhibitor or ARB (96%) and a beta-blocker (69%); MRA use was not reported.(149) † ICD treatment led to an RRR in death of 23% (P 1⁄4 0.”
- Epidemiology of Sudden Cardiac Death: Clinical and Research Implications (2008, background): “However, only 20–30% of patients that are implanted with a prophylactic ICD, actually receive appropriate therapies over a followup period of 4–5 years (47,51).”